A cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting β-agonist use in asthma
A cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting β-agonist use in asthma
复制标题
DOI：
10.1378/chest.126.4.1161
复制
发表时间：
2004-10-01
期刊：
影响因子：
9.6
通讯作者：
Anis, AH
中科院分区：
文献类型：
--
作者：
Lynd, LD;Sandford, AJ;Anis, AH
Study objective: To assess the association between socioeconomic status (SES) and short-acting (SA) P-agonist use, controlling for asthma severity.Design: Cross-sectional study.Setting: Vancouver, BC, Canada.Participants: Two hundred two asthmatics between 19 years and 50 years of age and residing in the greater Vancouver regional district.Measurements: The quantity of SA beta-agonist used in the previous year was collected by self-report; pulmonary function and beta-receptor genotype were measured on each participant. SES was measured at both the individual and population levels. Five methods of adjustment for asthma severity were used, as follows: the Canadian Asthma Consensus Guidelines, three previously developed asthma-severity scores, and forward stepwise multiple regression modeling. Polychotomous logistic regression was used to assess all relationships.Results: Independent of the method used to measure SES or adjust for asthma severity, lower SES was consistently and significantly associated with the use of greater amounts of SA beta-agonist. Adjusting for severity using the multivariate model explained the most variance of SA P-agonist use (R-2 adjusted, 0.35 to 0.37). In this model, social assistance recipients were more likely to use greater amounts of SA P-agonist (odds ratio [OR], 3.4; 95% confidence interval [CI], 1.7 to 6.5). An inverse relationship between SA P-agonist use and both annual household income (>$50,000; OR, 0.28; 95% CI, 0.13 to 0.60; and $20,000 to $50,000; OR, 0.44; 95% CI, 0.21 to 0.96; relative to
